Tonix Pharmaceuticals Holding Corp. Company Profile (NASDAQ:TNXP)

About Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Industry, Sector and Symbol:

Sector: Medical
Industry: Drug Manufacturers - Major
Sub-Industry: N/A
Symbol: NASDAQ:TNXP
CUSIP: N/A
Web: www.tonixpharma.com

Capitalization:

Market Cap: $31.97 million
Outstanding Shares: 7,486,000

Average Prices:

50 Day Moving Avg: $4.21
200 Day Moving Avg: $1.75
52 Week Range: $3.30 - $29.50

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -1.36
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: N/A
Price / Sales: N/A
Book Value: $6.47 per share
Price / Book: 0.66

Profitability:

EBIDTA: ($38,760,000.00)
Return on Equity: -140.86%
Return on Assets: -123.32%

Debt:

Current Ratio: 11.15%
Quick Ratio: 11.15%

Misc:

Average Volume: 1.33 million shs.
Beta: 2.92
Short Ratio: 3.68

Frequently Asked Questions for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

What is Tonix Pharmaceuticals Holding Corp.'s stock symbol?

Tonix Pharmaceuticals Holding Corp. trades on the NASDAQ under the ticker symbol "TNXP."

How were Tonix Pharmaceuticals Holding Corp.'s earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) released its earnings results on Monday, May, 15th. The company reported ($1.27) earnings per share for the quarter, topping the consensus estimate of ($1.36) by $0.09. View Tonix Pharmaceuticals Holding Corp.'s Earnings History.

Where is Tonix Pharmaceuticals Holding Corp.'s stock going? Where will Tonix Pharmaceuticals Holding Corp.'s stock price be in 2017?

3 analysts have issued 12-month price targets for Tonix Pharmaceuticals Holding Corp.'s shares. Their predictions range from $5.00 to $8.00. On average, they anticipate Tonix Pharmaceuticals Holding Corp.'s share price to reach $6.50 in the next twelve months. View Analyst Ratings for Tonix Pharmaceuticals Holding Corp..

Are investors shorting Tonix Pharmaceuticals Holding Corp.?

Tonix Pharmaceuticals Holding Corp. saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 602,690 shares, an increase of 84.5% from the March 31st total of 326,629 shares. Based on an average daily trading volume, of 1,360,665 shares, the short-interest ratio is currently 0.4 days.

Who are some of Tonix Pharmaceuticals Holding Corp.'s key competitors?

Some companies that are related to Tonix Pharmaceuticals Holding Corp. include Bovie Medical (BVX), Galmed Pharmaceuticals Ltd (GLMD), MEI Pharma (MEIP), CASI Pharmaceuticals (CASI), IntelliPharmaCeutics Intl (IPCI), Eiger Biopharmaceuticals (EIGR), KemPharm (KMPH), Flex Pharma (FLKS), Polarityte (COOL), ContraFect Corp (CFRX), Neuralstem (CUR), Bioline RX Ltd (BLRX), Joint Corp (JYNT), Zosano Pharma Corp (ZSAN), TRACON Pharmaceuticals (TCON), Ampio Pharmaceuticals (AMPE), Prima BioMed Ltd (PBMD) and Inotek Pharmaceuticals Corp (ITEK).

Who owns Tonix Pharmaceuticals Holding Corp. stock?

Tonix Pharmaceuticals Holding Corp.'s stock is owned by many different of retail and institutional investors. Top institutional shareholders include OPALEYE MANAGEMENT INC. (5.52%), Vanguard Group Inc. (1.91%), Kingdon Capital Management L.L.C. (0.86%), Renaissance Technologies LLC (0.64%), Dialectic Capital Management LP (0.53%) and Citadel Advisors LLC (0.34%). Company insiders that own Tonix Pharmaceuticals Holding Corp. stock include Bradley Saenger, Bruce Daugherty, Ernest Mario, Gregory M Sullivan, John B Rhodes, Leland Gershell and Seth Lederman. View Institutional Ownership Trends for Tonix Pharmaceuticals Holding Corp..

Who sold Tonix Pharmaceuticals Holding Corp. stock? Who is selling Tonix Pharmaceuticals Holding Corp. stock?

Tonix Pharmaceuticals Holding Corp.'s stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Kingdon Capital Management L.L.C. and Vanguard Group Inc.. View Insider Buying and Selling for Tonix Pharmaceuticals Holding Corp..

Who bought Tonix Pharmaceuticals Holding Corp. stock? Who is buying Tonix Pharmaceuticals Holding Corp. stock?

Tonix Pharmaceuticals Holding Corp.'s stock was purchased by a variety of institutional investors in the last quarter, including Dialectic Capital Management LP and Citadel Advisors LLC. Company insiders that have bought Tonix Pharmaceuticals Holding Corp. stock in the last two years include Bradley Saenger, Bruce Daugherty, Ernest Mario, Gregory M Sullivan, John B Rhodes, Leland Gershell and Seth Lederman. View Insider Buying and Selling for Tonix Pharmaceuticals Holding Corp..

How do I buy Tonix Pharmaceuticals Holding Corp. stock?

Shares of Tonix Pharmaceuticals Holding Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Tonix Pharmaceuticals Holding Corp. stock cost?

One share of Tonix Pharmaceuticals Holding Corp. stock can currently be purchased for approximately $4.27.

Consensus Ratings for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (?)

Ratings Breakdown:	3 Hold Ratings
Consensus Rating:	Hold (Score: 2.00)
Consensus Price Target:	$6.50 (52.22% upside)

Analysts' Ratings History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Show:

Date	Firm	Action	Rating	Impact on Share Price
12/20/2016	Oppenheimer Holdings Inc.	Reiterated Rating	Hold	N/A
9/7/2016	Roth Capital	Downgrade	Buy -> Neutral	N/A
9/7/2016	Cantor Fitzgerald	Downgrade	Buy -> Hold	N/A
6/30/2015	Janney Montgomery Scott	Reiterated Rating	Buy	N/A

(Data available from 5/23/2015 forward)

Earnings History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Earnings by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Earnings History by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
5/15/2017	Q1 2017	($1.36)	($1.27)	View	N/A
11/10/2016	Q3 2016	($0.34)	($0.29)	View	N/A
5/9/2016	Q1	($0.63)	($0.74)	View	N/A
3/4/2016	Q4	($0.66)	($0.71)	View	N/A
8/10/2015	Q215	($0.65)	($0.73)	View	N/A
5/11/2015	Q115	($0.54)	($0.71)	View	N/A
3/3/2015	Q414	($0.81)	($0.83)	View	N/A
11/10/2014	Q314	($0.69)	($0.71)	View	N/A
8/8/2014	Q214	($0.53)	($0.61)	View	N/A
5/13/2014	Q114	($0.35)	($0.59)	View	N/A
3/31/2014		($0.46)	($0.74)	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

2017 EPS Consensus Estimate: ($2.79)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	1	($0.83)	($0.83)	($0.83)
Q2 2017	1	($0.69)	($0.69)	($0.69)
Q3 2017	1	($0.65)	($0.65)	($0.65)
Q4 2017	1	($0.62)	($0.62)	($0.62)

(Data provided by Zacks Investment Research)

Dividend History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Insider Ownership Percentage: 10.20%
Institutional Ownership Percentage: 10.19%

Institutional Ownership by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Insider Trades by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
11/23/2016	Ernest Mario	Director	Buy	120,000	$0.41	$49,200.00
9/13/2016	Ernest Mario	Director	Buy	100,000	$0.79	$79,000.00
6/22/2016	Seth Lederman	CEO	Buy	20,000	$2.08	$41,600.00
6/21/2016	Bradley Saenger	CFO	Buy	2,000	$2.00	$4,000.00
6/21/2016	Bruce Daugherty	Insider	Buy	100,000	$2.00	$200,000.00
6/21/2016	John B Rhodes	Director	Buy	25,000	$2.00	$50,000.00
6/3/2016	Gregory M Sullivan	Insider	Buy	20,000	$2.50	$50,000.00
5/12/2016	Ernest Mario	Director	Buy	31,042	$2.30	$71,396.60
5/11/2016	Ernest Mario	Director	Buy	8,210	$2.24	$18,390.40
3/23/2016	Seth Lederman	CEO	Buy	8,000	$2.44	$19,520.00
3/16/2016	Ernest Mario	Director	Buy	75,000	$2.29	$171,750.00
9/30/2015	Gregory M Sullivan	Insider	Buy	5,000	$5.18	$25,900.00
9/28/2015	Gregory M Sullivan	Insider	Buy	4,694	$5.95	$27,929.30
9/25/2015	Seth Lederman	CEO	Buy	6,000	$6.50	$39,000.00
8/26/2015	Ernest Mario	Director	Buy	10,000	$6.05	$60,500.00
8/25/2015	Ernest Mario	Director	Buy	1,468	$6.40	$9,395.20
8/24/2015	Ernest Mario	Director	Buy	2,532	$6.20	$15,698.40
8/20/2015	Ernest Mario	Director	Buy	6,000	$6.64	$39,840.00
8/17/2015	Ernest Mario	Director	Buy	15,000	$6.93	$103,950.00
7/17/2015	John B Rhodes	Director	Buy	6,000	$7.50	$45,000.00
7/17/2015	Leland Gershell	CFO	Buy	1,000	$7.50	$7,500.00
6/11/2015	Gregory M Sullivan	Insider	Buy	4,500	$8.38	$37,710.00
3/17/2015	Seth Lederman	CEO	Buy	2,000	$7.02	$14,040.00
3/13/2015	Seth Lederman	CEO	Buy	2,000	$7.24	$14,480.00
3/11/2015	Seth Lederman	CEO	Buy	2,000	$6.95	$13,900.00
3/10/2015	Charles E Iv Mather	Director	Buy	1,000	$6.80	$6,800.00
3/9/2015	Seth Lederman	CEO	Buy	2,000	$6.48	$12,960.00
3/6/2015	Ernest Mario	Director	Buy	4,000	$6.57	$26,280.00
3/5/2015	Seth Lederman	CEO	Buy	2,000	$6.27	$12,540.00
2/9/2015	Ernest Mario	Director	Buy	30,000	$5.85	$175,500.00
2/9/2015	Leland Gershell	CFO	Buy	5,000	$5.85	$29,250.00
9/27/2013	Charles E Iv Mather	Director	Buy	1,000	$3.65	$3,650.00

(Data available from 1/1/2013 forward)

Headline Trends for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Latest Headlines for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Source:

Date	Headline
	Tonix Pharma (TNXP) Reports Analyses of Potential Moderators of ... - StreetInsider.com www.streetinsider.com - May 23 at 8:47 AM
	Tonix Pharma (TNXP) Reports Analyses of Potential Moderators of Treatment Response to TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD www.streetinsider.com - May 22 at 7:15 PM
	Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD finance.yahoo.com - May 22 at 7:15 PM
	Today's Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Calithera Biosciences finance.yahoo.com - May 22 at 8:33 AM
	Zacks Investment Research Analysts Decrease Earnings Estimates for Tonix Pharmaceuticals Holding Corp. (TNXP) www.americanbankingnews.com - May 22 at 7:18 AM
	Tonix Pharma up 7% premarket on institutional stakes seekingalpha.com - May 19 at 6:18 PM
	TNXP: Interim Analysis for HONOR Study Expected in 1H18 finance.yahoo.com - May 19 at 1:15 PM
	Tonix Pharmaceuticals Holding Corp. (TNXP) Announces Quarterly Earnings Results www.americanbankingnews.com - May 16 at 4:44 PM
	BRIEF-Tonix Pharmaceuticals reports Q1 loss per share $1.27 www.reuters.com - May 15 at 8:55 AM
	Tonix Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Programs Update finance.yahoo.com - May 15 at 8:54 AM
	Tonix reports 1Q loss finance.yahoo.com - May 15 at 8:54 AM
	Tonix Pharmaceuticals Holding Corp. (TNXP) Set to Announce Quarterly Earnings on Monday www.americanbankingnews.com - May 6 at 7:14 AM
	Tonix Pharmaceuticals Holding Corp. (TNXP) Expected to Post Earnings of -$1.10 Per Share www.americanbankingnews.com - May 3 at 12:02 PM
	TNX-102 SL is an FDA-Designated Breakthrough Therapy for PTSD in Phase 3 Development www.nasdaq.com - May 2 at 6:17 PM
	Tonix Pharmaceuticals Holding Corp. (TNXP) Earning Favorable News Coverage, Analysis Finds www.americanbankingnews.com - May 2 at 1:30 PM
	Tonix Pharmaceuticals Holding Corp. (TNXP) Sees Significant Growth in Short Interest www.americanbankingnews.com - May 2 at 11:36 AM
	Drug Makers Stocks Under Scanner -- Novartis, TherapeuticsMD, Tonix Pharma, and Retrophin www.bizjournals.com - May 2 at 8:52 AM
	Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-102 SL Composition and Formulation: Designed for Transmucosal Absorption and Bedtime Daily Use finance.yahoo.com - May 2 at 8:52 AM
	Research Analysts Issue Forecasts for Tonix Pharmaceuticals Holding Corp.'s Q1 2017 Earnings (TNXP) www.americanbankingnews.com - April 24 at 7:02 AM
	TNXP: Potential for Only One Phase 3 Trial Needed for TNX-102 SL in PTSD finance.yahoo.com - April 21 at 8:03 PM
	Tonix Pharmaceuticals Holding Corp. (TNXP) Given Media Sentiment Score of 0.12 www.americanbankingnews.com - April 21 at 6:12 PM
	Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update finance.yahoo.com - April 17 at 8:34 AM
	Tonix reports 4Q loss marketbeat.com - April 17 at 7:54 AM
	Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option finance.yahoo.com - April 13 at 8:08 PM
	Tonix Pharma (TNXP) Receives Official Minutes from FDA on Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 www.streetinsider.com - April 11 at 9:11 AM
	Tonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder finance.yahoo.com - April 11 at 9:11 AM
	Tonix Pipeline Review Closer to the Commercialization of a New PTSD Treatment finance.yahoo.com - April 7 at 1:03 PM
	Tonix Pharmaceuticals Completes $8 Million Public Offering of Common Stock finance.yahoo.com - April 7 at 1:03 PM
	Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement us.rd.yahoo.com - April 3 at 8:05 PM
	Is This The Start of a Turnaround for DryShips and Tonix, or will Management Burn Investors Again us.rd.yahoo.com - April 3 at 8:05 PM
	Tonix Pharmaceuticals: Good And Bad News - Seeking Alpha seekingalpha.com - April 1 at 6:41 AM
	Tonix Pharmaceuticals Prices Public Offering of 1,800,000 Shares of Common Stock us.rd.yahoo.com - March 31 at 3:32 AM
	TONIX PHARMACEUTICALS HOLDING CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Fin biz.yahoo.com - March 31 at 3:32 AM
	Tonix Pharmaceuticals Holding (TNXP) Has Surged To Nearly A 6-Month High www.rttnews.com - March 30 at 5:52 AM
	Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at The MicroCap Conference - GlobeNewswire (press release) globenewswire.com - March 29 at 7:19 AM
	Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at The MicroCap Conference finance.yahoo.com - March 29 at 7:19 AM
	Tonix Pharmaceuticals Holding Corp. (TNXP) Receives Average Rating of "" from Analysts www.americanbankingnews.com - March 28 at 11:46 AM
	Tonix Pharma (TNXP) Announces 1st Participant in Military-Related PTSD Phase 3 Trial of TNX-102 SL www.streetinsider.com - March 28 at 8:50 AM
	Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL us.rd.yahoo.com - March 28 at 8:50 AM
	Tonix Pharmaceuticals Holding (TNXP) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow seekingalpha.com - March 23 at 1:14 AM
	TONIX PHARMACEUTICALS HOLDING CORP. Financials finance.yahoo.com - March 21 at 8:02 PM
	Splits Calendar: Tonix Pharma splits before market open today (1:10 ratio) biz.yahoo.com - March 18 at 2:13 AM
	Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split us.rd.yahoo.com - March 17 at 1:43 AM
	TONIX PHARMACEUTICALS HOLDING CORP. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendmen biz.yahoo.com - March 17 at 1:43 AM
	Tonix Pharma (TNXP) Announces Composition & Manufacturing US Patent for TNX-102 SL - StreetInsider.com www.streetinsider.com - March 16 at 3:06 AM
	Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program at Oppenheimer’s 27th Annual Healthcare Conference finance.yahoo.com - March 15 at 8:07 AM
	BRIEF-Tonix Pharma receives notice of allowance for new U.S. Patent www.reuters.com - March 14 at 8:59 AM
	Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent Covering Composition and Manufacture of TNX-102 SL finance.yahoo.com - March 14 at 8:59 AM
	7:02 am Tonix Pharma announces that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application covering composition and manufacture of tnx-102 sl finance.yahoo.com - March 14 at 8:59 AM
	TONIX PHARMACEUTICALS HOLDING CORP. Files SEC form 8-K, Other Events, Financial Statements and Exhibits biz.yahoo.com - March 14 at 8:59 AM